No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.